Neurotoxicity of chemotherapeutic and biologic agents in children with cancer

Current Neurology and Neuroscience Reports

Volumn 8, Issue 2, 2008, Pages 114-122

  de Braganca, Kevin C ^a   Packer, Roger J ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON A; AMIFOSTINE; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; BIOLOGICAL FACTOR; CARBOPLATIN; CHLOROACETALDEHYDE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; ETOPOSIDE; FOLINIC ACID; GAMMA INTERFERON; GEMTUZUMAB OZOGAMICIN; IFOSFAMIDE; IRINOTECAN; ITRACONAZOLE; MAFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; RITUXIMAB; STEROID; THIOTEPA; TOPOTECAN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTERIOR HORN CELL DISEASE; ARACHNOIDITIS; BRAIN DISEASE; BRAIN TOXICITY; CANCER CHEMOTHERAPY; CAPILLARY HEMANGIOMA; CEREBELLUM DISEASE; CEREBRAL BLINDNESS; CHILD; CHILDHOOD CANCER; CHILL; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CRANIAL NEUROPATHY; DROWSINESS; DRUG CONTRAINDICATION; DRUG CROSS REACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG OVERDOSE; DRUG RESPONSE; DRUG TOLERABILITY; DYSAUTONOMIA; ENZYME DEFICIENCY; FEVER; GAIT DISORDER; GLIOMA; HALLUCINATION; HEADACHE; HEARING LOSS; HEREDITARY MOTOR SENSORY NEUROPATHY; HODGKIN DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; ILEUS; KIDNEY FAILURE; LEUKEMIA; LEUKOENCEPHALOPATHY; LIMB WEAKNESS; LOW DRUG DOSE; MEDULLOBLASTOMA; MENINGITIS; MENTAL HEALTH; MONONEUROPATHY; MUSCLE STRENGTH; MYCOSIS; NAUSEA; NECK PAIN; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; RADICULOPATHY; RENAL PROTECTION; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPINAL CORD DISEASE; SWEATING; TACHYCARDIA; TREATMENT OUTCOME; URINE INCONTINENCE; VEIN THROMBOSIS; VOMITING; WEAKNESS;

AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHILD; CYTOKINES; HUMANS; NEOPLASMS; NERVOUS SYSTEM DISEASES; TIME;

EID: 41549128889     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-008-0019-9     Document Type: Review

References (57)

1. National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at http://ctep.cancer.gov/reporting/ ctc_v30.html. Accessed November 1, 2007.
2. Casciato DA (editor): Manual of Clinical Oncology, edn 5. Philadelphia: Lippincott Williams & Wilkins; 2004.
3. Ettinger LJ, Freeman AI, Creaven PJ: Intrathecal methotrexate overdose without neurotoxicity: case report and literature review. Cancer 1978, 41:1270-1273.
4. Ruggiero A, Ruggiero A, Conter V, Milani M: Intrathecal chemotherapy with antineoplastic agents in children. Pediatr Drugs 2001, 3:237-246.
5. Haykin ME, Gorman M, van Hoff J, et al.: Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J Neurooncol 2006, 76:153-157.
6. Dufourg MN, Landman-Parker J, Auclerc MF, et al.: Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children. Leukemia 2007, 21:238-247.
7. Mahoney DH Jr, Shuster JJ, Nitschke R, et al.: Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - a Pediatric Oncology Group study. J Clin Oncol 1998, 16:1712-1722.
8. Lo Nigro L, Di Cataldo A, Schiliro G: Acute neurotoxicity in children with B-lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk protocols. Med Pediatr Oncol 2000, 35:449-455.
9. Winick NJ, Bowman WP, Kamen BA, et al.: Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 1992, 84:252-256.
10. Riva D, Giorgi C, Nichelli F, et al.: Intrathecal methotrexate affects cognitive function in children with medulloblastoma. Neurology 2002, 9:59:48-53.
11. Rutkowski S, Bode U, Deinlein F, et al.: Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005, 352:978-986.
12. Koh S, Nelson MD Jr, Kovanlikaya A, et al.: Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol 1999, 21:576-578.
13. van den Berg H, van der Flier M, van de Wetering MD: Cytarabine-induced aseptic meningitis. Leukemia 2001, 15:697-699.
14. Benesch M, Sovinz P, Krammer B, et al.: Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol 2007, 29:222-226.
15. Posner JB: Contemporary Neurology Series: Neurologic Complications of Cancer, Vol. 45. New York: Oxford University Press; 1995.
16. Hovi L, Era P, Rautonen J, et al.: Impaired muscle strength in female adolescents and young adults surviving leukemia in childhood. Cancer 1993, 72:276-281.
17. Kieslich M, Porto L, Lanfermann H, et al.: Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2003, 25:484-487.
18. Aytac S, Yetgin S, Tavil B: Acute and long-term neurologic complications in children with acute lymphoblastic leukemia. Turk J Pediatr 2006, 48:1-7.
19. Trinkle R, Wu JK: Errors involving pediatric patients receiving chemotherapy: a literature review. Med Pediatr Oncol 1996, 26:344-351.
20. Tabori U, Sung L, Hukin J, et al.: Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian Pediatric Brain Tumor Consortium Study. Cancer 2005, 103:1874-1880.
21. Riga M, Korres S, Psarommatis I, et al.: Neurotoxicity of BFM-95 on the medial olivocochlear bundle assessed by means of contralateral suppression of 2f1-f2 distortion product otoacoustic emissions. Otol Neurotol 2007, 28:208-212.
22. Schiavetti A, Frascarelli M, Uccini S, Novelli A: Vincristine neuropathy: neurophysiological and genetic studies in a case of Wilms tumor. Pediatr Blood Cancer 2004, 43:606-609.
23. Bermudez M, Fuster JL, Llinares E, et al.: Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol 2005, 27:389-392.
24. Bertolini P, Lassalle M, Mercier G, et al.: Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004, 26:649-655.
25. Brock PR, Bellman SC, Yeomans EC, et al.: Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 1991, 19:295-300.
26. Gilmer Knight KR, Kraemer DF, Neuwelt EA: Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005, 23:8588-8596.
27. Sastry J, Kellie SJ: Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 2005, 22:441-445.
28. Watterson J, Toogood I, Nieder M, et al.: Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer 1994, 74:3034-3041.
29. Razzouk BI, Heideman RL, Friedman HS, et al.: A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer 1995, 75:2762-2767.
30. Ridola V, Grill J, Doz F, et al.: High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer 2007, 110:156-163.
31. Valteau-Couanet D, Fillipini B, Benhamou E, et al.: High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. Bone Marrow Transplant 2005, 36:939-945.
32. Fagioli F, Biasin E, Mastrodicasa L, et al.: High-dose thiotepa and etoposide in children with poor-prognosis brain tumors. Cancer 2004, 100:2215-2221.
33. Modak S, Gardner S, Dunkel IJ, et al.: Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. J Clin Oncol 2004, 22:1934-1943.
34. Blaney SM, Heideman R, Berg S, et al.: Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 2003, 21:143-147.
35. Bomgaars LR, Bernstein M, Krailo M, et al.: Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2007, 25:4622-4627.
36. Vassal G, Couanet D, Stockdale E, et al.: Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol 2007, 25:356-361.
37. Pappo AS, Lyden E, Breitfeld P, et al.: Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol 2007, 25:362-369.
38. Bisogno G, Riccardi R, Ruggiero A, et al.: Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 2006, 106:703-707.
39. Gentet JC, Patte C, Quintana E, et al.: Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology. J Clin Oncol 1990, 8:661-665.
40. Simon T, Langler A, Berthold F, et al.: Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. J Pediatr Hematol Oncol 2007, 29:101-106.
41. McTiernan A, Meyer T, Michelagnoli MP, et al.: A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. Pediatr Blood Cancer 2006, 46:345-350.
42. Van Winkle P, Angiolillo A, Krailo M, et al.: Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 2005, 44:338-347.
43. Blaney SM, Balis FM, Berg S, et al.: Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol 2005, 23:1555-1563.
44. Slavc I, Schuller E, Czech T, et al.: Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 1998, 38:213-218.
45. Slavc I, Schuller E, Falger J, et al.: Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. J Neurooncol 2003, 64:239-247.
46. Nicolao P, Giometto B: Neurological toxicity of ifosfamide. Oncology 2003, 65(Suppl 2):11-16.
47. Pratt CB, Green AA, Horowitz ME, et al.: Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/ mesna. J Clin Oncol 1986, 4:1253-1261.
48. Pelgrims J, De Vos F, Van den Brande J, et al.: Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000, 82:291-294.
49. Arceci RJ, Sande J, Lange B, et al.: Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005, 106:1183-1188.
50. Giulino LB, Bussel JB, Neufeld EJ: Treatment with rituximab in benign and malignant hematologic disorders in children.; Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network. J Pediatr 2007, 150:338-344.
51. Byrd JC, Murphy T, Howard RS, et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001, 19:2153-2164.
52. Petropoulos D, Worth LL, Mullen CA, et al.: Interferon-alpha after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma. Bone Marrow Transplant 2006, 38:345-349.
53. Wilson MW, Hoehn ME, Haik BG, et al.: Low-dose cyclophosphamide and interferon alfa 2a for the treatment of capillary hemangioma of the orbit. Ophthalmology 2007, 114:1007-1011.
54. Ezekowitz RA, Mulliken JB, Folkman J: Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992, 326:1456-1463.
55. Wolff JE, Wagner S, Reinert C, et al.: Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol 2006, 79:315-321.
56. Kishi S, Cheng C, French D, et al.: Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007, 109:4151-4157.
57. Cheok MH, Evans WE: Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006, 6:117-129. Erratum in Nat Rev Cancer 2006, 6:249.